c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations (Q27649203)

1

0 references

Paula Kaplan-Lefko

2

0 references

Yajing Yang

3

0 references

Yihong Zhang

4

0 references

Jodi Moriguchi

5

0 references

Karen Rex

6

0 references

Carol W Johnson

7

0 references

Paul E Rose

8

0 references

Alexander M Long

9

0 references

Anne B O'Connor

10

0 references

Yan Gu

11

0 references

Angela Coxon

12

0 references

Tae-Seong Kim

13

0 references

Andrew Tasker

14

0 references

Teresa L Burgess

15

0 references

Isabelle Dussault

Journal of Biological Chemistry

16

0 references

language of work or name

English

0 references

publication date

1 February 2008

0 references

published in

0 references

volume

283

0 references

issue

5

0 references

page(s)

2675-83

0 references

cites work

Met, metastasis, motility and more

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Cancer therapy: can the challenge be MET?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Hereditary papillary renal carcinoma type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

The mutationally activated Met receptor mediates motility and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Activating mutations for the met tyrosine kinase receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

The Sema domain of Met is necessary for receptor dimerization and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Processing of X-ray diffraction data collected in oscillation mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200

Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M705774200